Clinical Research Directory
Browse clinical research sites, groups, and studies.
Therapy to Maintain Remission in Dilated Cardiomyopathy
Sponsor: Imperial College London
Summary
One third of patients diagnosed with heart failure demonstrate left ventricular reverse remodelling and recovery of cardiac function following a period of medical therapy. The TRED-HF trial investigated the impact of therapy withdrawal in this cohort and found that 40% of patients relapsed within 6 months of stopping treatment. In this follow-on study, the investigators will investigate the safety of therapy withdrawal of sodium cotransporter 2 inhibitors (SGLT2i) and mineralocorticord receptor anatagonists (MRAs) in patients with a previous diagnosis of heart failure and recovered cardiac function, in a randomised controlled trial to assess whether this maintains remission in this population.
Official title: A Randomised Trial Examining Therapy to Maintain Remission in Dilated Cardiomyopathy
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2023-12-02
Completion Date
2026-09-15
Last Updated
2024-09-19
Healthy Volunteers
No
Interventions
Other
Withdrawal of mineralocorticoid receptor antagonists and/or sodium glucose cotransporter 2 inhibitors
Locations (1)
Royal Brompton Hospital
London, United Kingdom